Key clinical point: Higher pretransplant red blood cell (RBC) and platelet transfusion burden has an independent association with higher overall and relapse-related mortality following allogeneic hematopoietic stem cell transplantation (allo-HSCT) for de novo myelodysplastic syndrome (MDS).
Major finding: A higher pretransplant RBC transfusion burden was significantly associated with lower overall survival (OS; P less than .001) and higher relapse-related mortality ( P less than .001). Similarly, a higher pretransplant platelet transfusion burden was associated with lower OS ( P less than .001) and higher relapse-related mortality ( P = .001).
Study details: A retrospective study examined the effects of pretransplant RBC and platelet transfusion burden on outcomes after allo-HSCT in 1,007 adults with de novo MDS.
Disclosures: This study was supported in part by the Practical Research Project for Allergic Diseases and Immunology (Research Technology of Medical Transplantation) from the Japan Agency for Medical Research and Development. The authors declared no conflicts of interest.
Source: Konuma T et al. Transplant Cell Ther. 2021 May 12. doi: 10.1016/j.jtct.2021.05.003 .